Floatz logo

Norfloxacin

Hepatorenal Syndrome

Hospital Clinic of BarcelonaSmall moleculePhase 4 / ApprovedDormant
BB
68/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
54/ 100
Competitive Position
89/ 100

Competitive context

5 Active assets in the Hepatorenal Syndrome cohort.

Asset / SponsorPhaseRating
GLY-GLY-GLY-CYS-TYR-PHE-GLN-ASN-CYS-PRO-LYS-GLY-NH2 (4-9 DISULFIDE)
Noorik Biopharmaceuticals AG
Phase 4A
NORMAL HUMAN SERUM ALBUMIN
Massachusetts General Hospital
Phase 4BBB
Octreotide Pamoate
University of California, Los Angeles
Phase 2/3BB
Midodrine
University of California, Los Angeles
Phase 2/3BB
[Phe^2,Ile^3,Dab(PhAc-D-Tyr(Me)-Phe-Gln-Asn-Ala-Pro-Arg-iGln-Lys(Ac)-Epsilon-Lys)^8]vasopressin
Ocelot Bio, Inc
Phase 2B

View all 11 →

Same molecule, other indications

Norfloxacin is also rated in:

peritonitisDormant
BBB
Indicative ·
78 / 100
View asset →
cirrhosis of liverDormant
BBB
Indicative ·
72 / 100
View asset →
esophageal varicesDormant
B
Indicative ·
60 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →